Anti-murine CD52 therapy provides anti-inflammatory and neuroprotective effects in EAE
MULTIPLE SCLEROSIS JOURNAL
Authors: Turner, M. J.; Chretien, N.; Havari, E.; Huang, J.; Pang, P.; LaMorte, M. J.; Garron, C.; Roberts, B. L.; Kaplan, J. M.; Siders, W. M.
Abstract
Targeted molecular therapy in peripheral T-cell lymphomas
EXPERT REVIEW OF HEMATOLOGY
Authors: Roncolato, Fernando; Gazzola, Anna; Zinzani, Pier Luigi; Pileri, Stefano A.; Piccaluga, Pier Paolo
Abstract
Peripheral T-cell lymphomas (PTCLs) are rare neoplasms constituting a heterogeneous group of diseases. At present, available chemotherapy regimens that have improved outcomes in B-cell lymphomas appear to be less efficacious in the context of PTCLs and, thus, alternative strategies are warranted. In the last few years, based on the recent, deeper understanding of PTCL biology, several molecules and/or pathways have been proposed for targeted therapy in this setting, including surface antigens, tyrosine kinases, the NF-kappa B pathway, folate metabolism, histone modification and others. Of particular interest, histone deacetylase and proteasome inhibitors, as well as novel chemotherapeutic agents such as pralatrexate, have already demonstrated efficacy in PTCL therapy. In addition, a strong biological rationale and early clinical evidence supports the future study of tyrosine kinase inhibitors in this setting. In this article, the authors review the available literature on targeted therapy in PTCLs and also, based on their own experience, discuss potential opportunities in this intriguing area.
COA
Publication 
Loading ......
